Clinical trials: Bladder, Overactive
Overactive Bladder
Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world…
- Trial name
- NCT05067478
- Testing
- Vibegron
- Where
- 64 sites in United States
- Volunteers
- 403 people
- Sponsor
- Urovant Sciences GmbH
Overactive Bladder (OAB)
Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)
A study to evaluate the safety and effectiveness of FemPulse System
- Trial name
- EVANESCE-II (NCT07195656)
- Testing
- Device Group, Medication Group
- Where
- 15 sites in United States
- Volunteers
- 151 people
- Sponsor
- FemPulse Corporation
Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB)
Vesitirim™ in Men Postmarketing Observational Study
This is an observational study which will look at the improvement in Lower Urinary Tract Symptoms (LUTS) in Irish men being treated with Vesitirim™ (solifenacin).
- Trial name
- VIM (NCT01639794)
- Testing
- Vesitirim™ (Solifenacin)
- Where
- 5 sites in Ireland
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Europe Ltd.
Overactive Bladder
Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2")
The study will investigate the safety and efficacy of UroGen's TC-3 Gel for sustained release of Botulinum Toxin A (BTX) in urinary bladder in patients with idiopathic overactive bladder.
- Trial name
- INTIMO2 (NCT02674269)
- Testing
- 300 IU of BotuGelTM (60ml), 400 IU of BotuGelTM (60ml), TC-3 Gel
- Where
- 2 sites in Israel
- Sponsor
- UroGen Pharma Ltd.
Overactive Bladder
An Implantable Microstimulator for the Chronic Treatment of Urinary Urgency-Frequency Syndrome
The goal of this study is to investigate the safety and effectiveness of a new implanted device designed to treat Urinary Urgency-Frequency Syndrome.
- Trial name
- NCT00131573
- Testing
- bion
- Where
- 11 sites in United States
- Volunteers
- 118 people
- Sponsor
- Boston Scientific Corporation
Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy
Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia
To evaluate the efficacy and safety of solifenacin succinate as add-on therapy for overactive bladder (OAB) symptoms in men who have been treated for benign prostatic hyperplasia (BPH) with tamsulosin hydrochloride for at least 6…
- Conditions
- Benign Prostatic Hyperplasia, Benign Prostatic Hypertrophy, Overactive Bladder
- Trial name
- NCT00771394
- Testing
- Tamsulosin hydrochloride, Solifenacin succinate
- Where
- 8 sites in Japan
- Volunteers
- 638 people
- Sponsor
- Astellas Pharma Inc
Urinary Incontinence, Urinary Obstruction
NXT Post-Market Clinical Follow-up
NXT Urodynamics System Post-Market Clinical Follow-up Clinical Investigation to Confirm Ongoing Safety and Performance in Urodynamic Patient Sub-Populations
- Conditions
- Urinary Incontinence, Urinary Obstruction, Urinary Bladder, Overactive, Urinary Bladder, Neurogenic
- Trial name
- NCT06336304
- Testing
- Urodynamic procedure
- Where
- 5 sites in United States
- Volunteers
- 163 people
- Sponsor
- Laborie Medical Technologies Inc.
Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)
A Cost Analysis of Interstim Therapy
A study to examine the impact that Interstim Therapy for Urinary Control has on health care utilization and costs within a health care system and the satisfaction with treatment expressed by patients using this therapy.
- Trial name
- NCT00200031
- Testing
- Interstim therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder
This study is designed to assess the efficacy and safety of a flexible dose regimen of fesoterodine on urgency urinary incontinence (UUI) episodes in vulnerable elderly subjects with overactive bladder (OAB).
- Trial name
- NCT00928070
- Testing
- Fesoterodine
- Where
- 125 sites in United States
- Volunteers
- 566 people
- Sponsor
- Pfizer
Urinary Bladder, Overactive
FemPulse Therapy for Overactive Bladder in Women
The purpose of this clinical trial is to investigate a new medical device treatment for Overactive Bladder (OAB) in women.
- Trial name
- EVANESCE-OAB (NCT03784170)
- Testing
- FemPulse System
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- FemPulse Corporation
Overactive Bladder
Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.
With this study researchers want to gather information about the consumer use behavior of Oxytrol in a simulated setting in which the medicine is sold directly to a consumer without a prescription from a healthcare professional.
- Trial name
- NCT04534491
- Testing
- Oxybutynin (Oxytrol, BAY839380)
- Where
- United States
- Volunteers
- 855 people
- Sponsor
- Bayer
Overactive Bladder, Overactive Bladder (OAB)
Detrusor Nerve Radiofrequency Ablation for Overactive Bladder in Women
The goal of this clinical trial is to learn if a vaginal radiofrequency (RF) device called MORPHEUSV works to treat overactive bladder (OAB) in women. Researchers also want to learn how safe the device is for this indication.
- Conditions
- Overactive Bladder, Overactive Bladder (OAB), Urge Urinary Incontinence, Mixed Urinary Incontinence (Urge-Predominant)
- Trial name
- DENARA (NCT07209397)
- Testing
- Detrusor nerve radiofrequency ablation
- Where
- 9 sites in United States
- Volunteers
- 202 people
- Sponsor
- InMode MD Ltd.
Urinary Incontinence
A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007)
Overactive bladder is very prevalent in postmenopausal women. The current study is designed to investigate whether a new drug may offer safe and effective treatment.
- Trial name
- NCT00231790
- Testing
- MK-0634 50 mg, MK-0634 125 mg
- Volunteers
- 848 people
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Retention, Urinary Urge Incontinence
Axonics SacRal NeuromodulaTIon System RegisTRY Study
To assess the post-market clinical outcomes with use of the Axonics Sacral Neuromodulation System(s).
- Conditions
- Urinary Retention, Urinary Urge Incontinence, Urgency-Frequency, Fecal Incontinence
- Trial name
- ARTISTRY (NCT05064384)
- Where
- 27 sites in United States, Canada
- Volunteers
- 272 people
- Sponsor
- Axonics, Inc.
Healthy Volunteer, Pharmacokinetics of YM178
A Study to Investigate the Safety and Effect of Food on the Pharmacokinetics of YM178 in Healthy Volunteers
The purpose of the study is to evaluate safety of YM178 and the effect of food intake on the pharmacokinetics of YM178 in healthy adult subjects.
- Trial name
- NCT01334905
- Testing
- YM178
- Where
- Taiwan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Inc
Overactive Bladder, Urge Incontinence
Treatment of Overactive Bladder With a Digital Conversational Agent: the MOTIVATION Study
This is a proof of concept study for a digital therapeutic designed to provide first-line behavioral modification therapy for overactive bladder.
- Conditions
- Overactive Bladder, Urge Incontinence, Pelvic Floor Disorders
- Trial name
- MOTIVATION (NCT04853849)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Renalis
Urinary Bladder, Overactive
Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity
This study will evaluate the efficacy and safety of GSK1358820 in Japanese patients with neurogenic detrusor overactivity (NDO) with urinary incontinence, whose symptoms have not been adequately managed with medications for…
- Trial name
- NCT02849418
- Testing
- GSK1358820
- Where
- 9 sites in Japan
- Volunteers
- 21 people
- Sponsor
- GlaxoSmithKline
Treatment of Patients Suffering From Overactive Bladder (OAB)
BlueWind RENOVA iStim™ System for the Treatment of OAB
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with…
- Trial name
- OASIS (NCT03596671)
- Testing
- RENOVA iStim™ System
- Where
- 23 sites in United States, Belgium and 2 more
- Volunteers
- 282 people
- Sponsor
- BlueWind Medical
Overactive Bladder
Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency
The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the study product, AOBO-001, when taken by adults with symptoms of overactive bladder. AOBO-001, is experimental, which means that the U. S.
- Trial name
- NCT01294982
- Testing
- AOBO-001
- Where
- 5 sites in United States
- Volunteers
- 66 people
- Sponsor
- American Oriental Bioengineering, Inc.
Urinary Tract Infections
Comparison of Pre-procedural PCR and Culture-based UTI Assessment Prior to Intravesical Botox Injection
This study is a retrospective record review to determine whether a novel multiplex PCR assay can be utilized as a screening method for UTI in patients receiving Botox injection to treat overactive bladder (OAB).
- Trial name
- NCT04817865
- Testing
- Multiplex-PCR with Pooled Antibiotic Susceptibility Testing (M-PCR/P-AST), Urine Culture
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Pathnostics